Gene Expression Profiling in Normal Tissue and Tumor Tissue From Patients With Colon Cancer That Has Spread to the Liver, Lungs, or Peritoneum
RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer may help doctors identify biomarkers related to cancer.
PURPOSE: This laboratory study is using gene expression profiling to evaluate normal tissue and tumor tissue from patients with colon cancer that has spread to the liver, lungs, or peritoneum.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Gene Expression Profiling of Metastatic Colon Cancer (CCCWFU 89B03)|
- Gene expression changes that occur at each metastatic site (i.e., liver, lungs, and peritoneum) [ Time Frame: day 1 ] [ Designated as safety issue: No ]
- Development of cell lines from primary colon tumors metastatic to the liver, lungs, or peritoneum [ Time Frame: day 1 ] [ Designated as safety issue: No ]
|Study Start Date:||September 2003|
|Study Completion Date:||May 2008|
|Primary Completion Date:||September 2006 (Final data collection date for primary outcome measure)|
|patients with metastatic colon cancer|
- Evaluate gene expression profiles in normal and tumor tissue from patients with colon cancer metastatic to the liver, lungs, or peritoneum.
- Establish cell lines from primary colon tumors metastatic to the liver, lungs, or peritoneum.
- Determine the specific gene expression changes that result in the manifestation of the drug-resistant phenotype for each metastatic site.
OUTLINE: This is a pilot study.
Tumor and normal tissue collected during surgery are analyzed for gene expression profiling by cDNA microarray. Tissue is also analyzed for thymidylate synthase (TS) gene expression by quantitative PCR and for protein expression by western blot. Gene expression patterns are correlated with TS levels.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00896753
|Study Chair:||Perry Shen, MD||Comprehensive Cancer Center of Wake Forest University|